Obesity drug developer Corxel Pharmaceuticals will go public in the United States through a merger with special purpose acquisition company Amanat Acquisition Corp, the companies announced on October 26, 2026. Corxel is expected to receive roughly $377 million from the SPAC deal and a concurrent private investment in public equity (PIPE), with institutional investors committing $300 million. The deal is anticipated to close in the first half of 2027, and the combined company will likely list on Nasdaq under a new name and ticker, both still to be announced.
The transaction values Corxel's equity at an implied $200 million, according to TradingView's account of the business combination agreement. Amanat currently trades on Nasdaq under the symbol AMAN.
The Drug: A Once-Daily Oral GLP-1 Pill
Corxel's lead candidate is CX11, a small-molecule agonist of the GLP-1 receptor, formulated as a once-daily pill. It is being developed for obesity, type 2 diabetes, and related cardiometabolic conditions, and the company is advancing it into late-stage development. CX11 has already completed Phase 3 testing in Asia, according to MedCity News.
In preliminary Phase 2 results in obesity, CX11 produced up to 11.5% weight loss at 36 weeks. With all the usual caveats about cross-trial comparisons, that figure is competitive with Phase 2 results from the now-approved GLP-1 pills — Novo Nordisk's oral peptide version of Wegovy and Eli Lilly's oral small molecule. Corxel's investor presentation also highlights tolerability: vomiting rates of 12% to 16% in mid-stage testing, which the company describes as markedly lower than those reported for the Novo and Lilly pills.
That combination — efficacy, tolerability, and scalability — is Corxel's pitch. The weight-loss market is dominated by Novo Nordisk and Eli Lilly, and the success of newer weight-loss therapies has spurred a wave of investment by biotechs trying to capture a slice of the sector. But the injectable era is giving way to an oral era, and pills change the economics: no cold chain, no injections, easier manufacturing at scale, and a much larger addressable population of patients who will not inject themselves.
The Financing: Why a SPAC, and Why Now
A SPAC is a shell company that raises capital through its own IPO and then merges with a private company, taking it public without a traditional IPO. The structure fell out of favour after the 2021 boom, when many SPAC mergers disappointed, but it has been quietly returning for companies with a specific need: a large, committed financing package in a single transaction.
Corxel's deal is a textbook example. The $300 million PIPE — money committed by institutional investors alongside the merger — is the real financing event; the SPAC trust account supplies the rest. Leerink Partners is serving as lead placement agent for the PIPE, with Evercore ISI, Guggenheim Securities, Cantor, and LifeSci Capital acting as placement agents. For a biotech about to enter expensive Phase 3 trials, certainty of funding matters more than the prestige of a traditional IPO roadshow.
The Risks: Phase 3 Is Where Obesity Dreams Get Tested
Nothing here is proven yet. Phase 2 weight-loss data, however encouraging, is not Phase 3 data, and obesity trials have a long history of candidates that looked strong mid-stage and faded on larger, longer studies. Corxel must also compete against two of the best-resourced pharmaceutical companies on earth, both of which already have approved oral products and deep commercial machines. Tolerability advantages help, but payers and physicians ultimately decide on long-term outcomes data, not single-trial side-effect rates.
The deal is also still subject to approvals and closing conditions, and the combined company's name, ticker, and final capital structure will only be set before closing.
What It Means for Founders and Investors
For biotech founders, Corxel's path is a reminder that the SPAC route is not dead — it is simply repriced. The 2026 version of a SPAC deal comes with a large, institutionally anchored PIPE and a modest implied equity value, not the billion-dollar headline valuations of 2021. Founders who can anchor real institutional demand can still use the structure to reach public markets on a defined timetable.
For investors, the deal is a pure-play bet on the oral GLP-1 transition. The question is not whether the obesity market is large — it plainly is — but whether a third entrant with a tolerability edge can carve out durable share against incumbents who are already scaling oral manufacturing. The $300 million PIPE suggests institutions think it is worth funding the attempt.
Angeled.com connects founders with investors.
Reuters, "Obesity drug developer Corxel to go public in US via SPAC deal" (October 26, 2026)
Source: medcitynews.com
MedCity News, "Obesity Biotech Corxel Is Going Public in a Merger as Oral GLP-1 Heads to Phase 3" (October 26, 2026)
Source: tradingview.com
TradingView News, "Amanat Acquisition to Merge With Corxel at $200 Million Implied Equity Value" (October 26, 2026)
Read Next
Inovalon to Acquire DrFirst, Uniting Healthcare Data With Prescribing Workflows
Oura to Acquire Counsel Health for $625 Million, Putting a Doctor Behind the Ring
Anthropic Files Updated IPO Prospectus Aiming at a $1.4 Trillion Valuation
Archrock to Acquire HiVolt Energy for Up to $450 Million
Barrick Mining Files to Spin Off and List Its North American Gold Business
What a $1.4 Trillion Anthropic IPO Would Mean for Founders



